Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Miravo Healthcare
Finance Watch: VC Round Extensions Attractive While Stock Market Wobbles
Private Company Edition: While Coya Therapeutics raised $15.25m in the final initial public offering in the US last year, Apnimed stayed private raising $80m in a series C extension and Metagenomi extended its series B by $100m to total $275m.
Dr Reddy’s Debuts US Vimovo Rival At Risk
Dr Reddy’s has announced the launch of the first US generic version of Vimovo delayed-release tablets. However, Nuvo has warned that the at-risk launch infringes patents protecting the arthritis pain treatment until May 2022.
Reddy’s, Lupin And Mylan Clear Two Vimovo Patents From Path
Three generics players in the US have helped to clear the path for generic rivals to the Vimovo analgesic by winning an appeals verdict of written descriptions for two patents.
Deal Watch: Harbour Expands Horizons Beyond China
Antibody developer Harbour Biomed signs its first deal for rights outside China in cancer pact with Kelun. Portage buys SalvaRx to increase its immuno-oncology capabilities, while Paragon spinout Emalex will take over Psyadon’s pediatric Tourette syndrome program.
- Medical Devices
- Drug Delivery
- OTC, Consumer
- Specialty Pharmaceuticals
- Controlled Release
- Topical Delivery
- Other Names / Subsidiaries
- Dimethaid Research
- Nuvo Ireland
- Nuvo Research, Inc.
- Nuvo Pharmaceuticals, Inc.
- Oxo Chemie GmbH
- Tribute Pharmaceuticals Canada Inc.
- ZARS Pharma, Inc.,
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.